Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites the potential of the company’s lead commercial drug, Zepzelca targeting small cell lung cancer, to obtain additional regulatory approvals, significantly increasing its addressable market for the Buy rating.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHMMF: